Overview

* Gilead Q3 2025 total revenue rises 3% yr/yr to $7.8 bln

* Adjusted EPS for Q3 2025 beats analyst expectations, per LSEG data

* Product sales excluding Veklury increase 4% to $7.1 bln

Outlook

* Gilead raises full-year product sales guidance to $28.4 bln-$28.7 bln

* Company increases full-year diluted EPS guidance to $6.65-$6.85

* Gilead anticipates multiple product launches in 2026

Result Drivers

* HIV SALES - HIV product sales increased 4% to $5.3 bln, driven by higher demand and favorable inventory dynamics, though offset by lower average realized price

* LIVER DISEASE SALES - Liver Disease portfolio sales rose 12% to $819 mln, mainly due to higher demand for Livdelzi

* VEKLURY DECLINE - Veklury sales dropped 60% to $277 mln, attributed to lower COVID-19-related hospitalizations

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 $7.34

Product bln

Sales

Q3 Beat $2.47 $2.13

Adjusted (19

EPS Analysts

)

Q3 EPS $2.43

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 23 "strong buy" or "buy", 7 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the pharmaceuticals peer group is "buy"

* Wall Street's median 12-month price target for Gilead Sciences Inc ( GILD ) is $131.00, about 9.5% above its October 29 closing price of $118.50

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)